Ob/Gyn Articles

Ob/Gyn

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Alwan S et al. - Maternal SSRI treatment during the first trimester has been implicated in increased risks of birth defects, specifically cardiac abnormalities, in the infant, whereas third-trimester treatment has been linked to various neonatal complications, including symptoms of neonatal withdrawal and toxicity, prematurity, low birth weight and persistent pulmonary hypertension of the newborn. Although data on neurobehavioural and long-term cognitive problems among children of women who were treated with SSRIs during pregnancy remain limited, the possibility of such functional abnormalities is an additional concern. On the other hand, untreated maternal depression also carries serious risks for both the mother and the baby, and SSRIs are one of the best available treatments. Thus, pregnant women who require treatment for depression and their physicians often face a difficult choice regarding the use of SSRIs.


Today in Maternal Fetal Medicine...keeping you current

Pregnancy and Inflammatory Bowel Disease
Gastroenterology Clinics of North America, 11/16/09

Trauma in Pregnancy
Clinical Obstetrics and Gynecology, 11/05/09

Thromboembolism and thrombophilia in pregnancy
Obstetrics, Gynaecology & Reproductive Medicine, 11/23/09

Today in Obstetrics...keeping you current

Pregnancy and Inflammatory Bowel Disease
Gastroenterology Clinics of North America, 11/16/09

Can pregnant diabetics be treated with glyburide?
Women's Health, 11/02/09

Gestational Diabetes
JAMA, 11/25/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address